MET-097 / Metsera, Amneal - LARVOL DELTA

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Metsera

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Metabolic Disorders

MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Preclinical • Metabolic Disorders

A Twelve-Week Trial of MET097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Metabolic Disorders

Safety, Tolerability, PK, and Efficacy of MET097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Metabolic Disorders

VESPER-2: A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (clinicaltrials.gov) - P2 | N=125 | Recruiting | Sponsor: Metsera

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress (GlobeNewswire) - "VESPER-1, a 28-week Phase 2b clinical trial, is designed to assess the efficacy and tolerability of different titration-free weekly doses of MET-097i. The trial includes 239 participants with obesity or overweight without type 2 diabetes. The last participant in VESPER-1 was enrolled in December 2024, with preliminary data expected in mid-2025....VESPER-3 is a planned Phase 2b clinical trial designed to evaluate the efficacy and tolerability of multiple monthly doses of MET-097i after multiple weekly doses with and without titration. Preliminary results are expected by year-end 2025 or early 2026."

P2b data • Obesity

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity (clinicaltrials.gov) - P1/2 | N=262 | Active, not recruiting | Sponsor: Metsera

New P1/2 trial • Genetic Disorders • Obesity

CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases (ACCESSWIRE) - "CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatments for obesity and metabolic diseases, in support of its recent Phase 2a and Phase 2b clinical trials of MET-097. MET-097 is an ultra-long-acting injectable, fully-biased GLP-1 receptor agonist designed to address the growing global challenge of obesity."

Commercial • Obesity

VESPER-1: A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 (clinicaltrials.gov) - P2 | N=225 | Active, not recruiting | Sponsor: Metsera | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A 16-week Phase 2b Study to Examine the Safety and Efficacy of Four Different Regimens of Once-Weekly MET097 (clinicaltrials.gov) - P2 | N=225 | Recruiting | Sponsor: Metsera

New P2 trial • Genetic Disorders • Obesity